Everest Medicines (HKSE:01952) ROCE % : -14.75% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Everest Medicines's annualized ROCE % for the quarter that ended in Dec. 2023 was -14.75%.

Everest Medicines ROCE % Historical Data

The historical data trend for Everest Medicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines ROCE % Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-19.25

-127.72

-14.95

-3.80

-14.49

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-18.43	-22.67	15.30	-14.10	-14.75

Everest Medicines ROCE % Calculation

Everest Medicines's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-898.434	/	( ( (7386.775 - 971.57)	+	(6314.136 - 328.273) )	/ 2 )
	=	-898.434	/	( (6415.205	+	5985.863)	/ 2 )
	=	-898.434	/	6200.534
	=	-14.49 %

Everest Medicines's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-903.242	/	( ( (6446.312 - 183.004)	+	(6314.136 - 328.273) )	/ 2 )
	=	-903.242	/	( ( 6263.308	+	5985.863 )	/ 2 )
	=	-903.242	/	6124.5855
	=	-14.75 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Everest Medicines (HKSE:01952) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Everest Medicines ROCE % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines